| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA538: Dinutuximab beta for treating neuroblastoma |
|
Medicine details |
|
| Medicine name | dinutuximab (Unituxin®) |
| Formulation | 3.5 mg/ml concentrate for solution for infusion |
| Reference number | 2793 |
| Indication | Treatment of high-risk neuroblastoma in patients aged 12 months to 17 years, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and autologous stem cell transplantation. It is administered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and isotretinoin |
| Company | United Therapeutics Corp |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 24/07/2015 |
| NICE guidance | |